Chinese biomedical companies are emerging as major competitors in the race to treat Parkinson's disease, a market valued at $16 billion. They are developing various advanced therapies, including cell and gene therapies, challenging existing Western pharmaceutical dominance.

Chinese biomedical companies deploying cutting-edge technologies are emerging as serious competitors to Western dominance in the race to treat Parkinson’s disease, in a market that could reach US$16 billion over the next decade. The firms are developing a range of approaches – from autologous cell therapies made from a patient’s own cells and ready-made cell products to gene therapies and non-invasive ultrasounds – although many of these candidates are still in early-stage trials. Many patients....